Biotechnology

TYK MEDICINES-B

Three CDKi Drugs Early Clinical Trial Results of Tongyuankang Biopharma-B Presented at ESMO Annual Meeting

TYK MEDICINES-B released FY2025 Q1 earnings on August 31, 2025 (BJT) with actual revenue of HKD 0 and EPS of HKD -0.1619

Tongyuankang Biopharma-B Announces 2025 H1 Results and R&D/Production Progress

TYK MEDICINES-B released FY2025 Semi-Annual Earnings on August 31 During-Market (BJT), with actual revenue HKD 0 and actual EPS HKD -0.3275

TYK MEDICINES-B released FY2025 Q2 earnings on August 31 During-Market BJT, actual revenue HKD 0, actual EPS HKD -0.1641

TYK MEDICINES-B to Release FY2025 Semi-Annual Earnings on August 31, 2025 (BJT)

Tongyuan Kang Medicine's Edocaitinib Shows Breakthrough in Treating Brain Metastatic Lung Cancer

Tongyuankang Biopharma-B Completes Placement Raising HKD 155 Million

Tongyuan Kang Medicine-B Conducts Share Placement

Tongyuankang Biopharma Receives BB ESG Rating

Homology Meds TY-9591 Outperforms Osimertinib at ASCO Annual Meeting

Dr. Zhu Xiangyang Appointed as Non-Executive Director of Tongyuankang Pharmaceutical-B

Tonhonkang Biopharma-B stock surges, TY-9591 shows positive clinical results

Tongyuankang Pharma-B applies to convert 4.608 million non-listed shares to H-shares

Tongyuankang Biopharma Inc. Included in Hang Seng Biotechnology Index

Tongyuankang Biopharma Participates in Establishing a Biomedicine Fund

Torunke Pharma Submits Pre-NDA Application for AEDTINIB

Tongyuankang Medicine's Core Product TY-9591 Research Results Selected for ASCO Conference

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Will Showcase the Latest Research Results of TY-9591

Zhejiang Tongyuan Kang Pharmaceutical Releases 2024 Performance and TY-9591 Clinical Trial Progress

LEGEND UPSTAR

ALMANA

DESIGN CAPITAL

CN SCI-TECH IND

ASIA PIONEER

NUR HOLDINGS

HUICHENG INTL H

ORIENTAL PAY

GLOBAL CORN GP

KINERGY

BEONE MEDICINES

INNOVENT BIO

3SBIO

BIOCYTOGEN-B

HBM HOLDINGS-B

ALPHAMAB-B

ABBISKO-B

ESSEX BIO-TECH

JIUYUAN GENE

GENOR-B

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap